The NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III ...

A new approach to cancer treatment became available shortly before Jimmy Carter needed it. Now it's a pillar of care.

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

Panelists discuss how the combination of Tivozanib plus Nivolumab from the TiNivo-2 study, along with other data presented at ...

Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to ...

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly ...

Nivolumab plus ipilimumab can provide long-term benefits to patients with advanced melanoma, according to a 10-year update of the CheckMate 067 trial.

During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the 2024 update to the RELATIVITY-047 trial in advanced ...

Nivolumab, given with or without ipilimumab, showed durable 10-year survival outcomes in patients with advanced melanoma.

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment ...

Researchers compared health-related quality of life with nivolumab added to first-line chemo vs chemo alone in patients with ...